E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment of patients with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum (PXE) |
|
E.1.1.1 | Medical condition in easily understood language |
ABCC6 Deficiency causing a condition called Pseudoxanthoma elasticum |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10037150 |
E.1.2 | Term | Pseudoxanthoma elasticum |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Assess the safety and tolerability of multiple ascending subcutaneous (SC) doses of INZ-701 |
|
E.2.2 | Secondary objectives of the trial |
• Assess the immunogenicity of multiple ascending SC doses of INZ-701. • Study the pharmacokinetics (PK) of INZ-701 administered as multiple SC doses. • Study the long-term safety and pharmacodynamic (PD) changes in pyrophosphate (PPi) and associated biomarkers of ABBC6 Deficiency after administration of multiple SC doses of INZ-701.
Exploratory Objectives:
• Assess changes in calcification of arteries and organs (including the eye). • Assess changes in clinical measures associated with underlying ABCC6 Deficiency, including skeletal, cardiac, vascular, hearing, ophthalmologic, and renal parameters. • Assess changes in physical function. • Assess changes in patient, clinician, and caregiver reported outcomes and quality of life. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Must provide written or electronic consent after the nature of the study has been explained, and prior to any research-related procedures, following International Conference on Harmonisation (ICH) Good Clinical Practice (GCP). 2. Clinical diagnosis of PXE supported by prior or concurrent genetic identification of biallelic Abcc6 mutations 3. Male or female, ages 18 to <65 years of age at Screening 4. Plasma PPi < lower limit of normal (LLN) at screening 5. Women of child-bearing potential (WOCBP as defined in CTFG 2014) must have a negative serum pregnancy test at Screening and negative urine pregnancy tests at all additional pregnancy tests during the study. 6. WOCBP and partners of fertile males who are WOCBP must agree to use 2 highly effective forms of contraception (per CTFG 2014) from at least 1 month before the first dose of INZ-701 through 30 days after last dose of INZ-701 (greater than 5 half-lives of INZ-701). WOCBP and partners of fertile males who are WOCBP must also agree to not donate ova from the period following the first dose of INZ-701 through 30 days after last dose of INZ-701 7. Males who are sexually active must agree to use condoms from the period following first dose of INZ-701 through 30 days after the last dose of INZ-701. Males must also agree to not donate sperm from the period following the first dose of INZ-701 through 30 days after last dose of INZ-701. 8. In the opinion of the Investigator, must be willing and able to complete all aspects of the study 9. Agree to provide access to relevant medical records |
|
E.4 | Principal exclusion criteria |
1. In the opinion of the Investigator and/or Sponsor, presence of any clinically significant disease (outside of those considered associated with the diagnosis of ABCC6 Deficiency) that precludes study participation or may confound interpretation of study results, including uncontrolled thyroid disease or unrelated connective tissue, bone, mineral, ophthalmologic, or muscle disease 2. Advanced eye disease requiring anti-VEGF treatment at Screening 3. Clinically significant abnormal laboratory result at screening, including but not limited to elevations of aspartate aminotransferase, alanine aminotransferase, bilirubin, or creatinine greater than 2 times the upper limit of normal, 25 (OH) Vitamin D levels <20 ng/mL, parathyroid hormone (PTH) more than 20% above the upper limit of normal, and hyper- or hypocalcemia 4. Known active fungal, bacterial, and/or viral infection including human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or COVID-19 virus. A negative COVID-19 test result is required within 5 days of first dose of INZ-701 5. Known intolerance to any INZ-701 excipient 6. Unable or unwilling to discontinue the use of any prohibited medication (examples include bisphosphonates, calcimimetics, antacids, systemic corticosteroids, pyrophosphate containing medications), as provided in protocol Section 9.4 7. Receipt of any other investigational new drug within 5 half-lives of the last dose of the other investigational drug or from 4 weeks prior to the first dose of INZ-701, whichever is longer, or use of an investigational device through completion of participation in the study 8. Last symptoms from a COVID-19 vaccination within 14 days prior to the first dose of INZ-701 or as described in the Inozyme COVID-19 Vaccine Guidance Document 9. Women who are breastfeeding |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety and Immunogenicity:
Safety assessments will be summarized at Baseline and at each observed time point. Safety variables include: • Changes from baseline in the terminal elimination half-life (clearance) of INZ701 • Changes from baseline in the ENPP1 enzyme activity and mass ratio (neutralizing anti-drug antibodies [ADA]) • Incidence, frequency, and severity of adverse events (AEs), treatment-related AEs, and serious adverse events (SAEs) • Vital signs and weight • Physical examinations • Estimated glomerular filtration rate (eGFR) • Laboratory tests including chemistry, hematology, and urinalysis, including additional biochemical parameters of interest • Anti-INZ-701 antibody testing and dose-limiting toxicities (DLTs) • Incidence of any anti-drug antibodies (ADA) • Incidence of treatment emergent adverse events (TEAEs) associated with hypersensitivity reactions • Concomitant medications • Electrocardiogram (ECG)
Pharmacokinetic Endpoints:
• INZ-701 plasma concentration-time profiles and determination of noncompartmental PK parameters (including Tmax, Cmax, AUClast, AUCtau, AUCinf, T1/2, Cmin, Cl/F, and V/F) • Assess linearity between ascending INZ-701 SC doses and PK parameters
Pharmacodynamic Endpoints:
• Change from baseline for plasma PPi levels • Changes from baseline for renal clearance of PPi, Pi, calcium normalized to blood and urine creatinine • Changes from baseline for blood and urine biomarkers − Serum 1,25(OH)2D, plasma ionized and total calcium, parathyroid hormone − Bone biomarkers: serum alkaline phosphatase (ALP), bone specific alkaline phosphatase (BALP), carboxy terminal cross-linked telopeptide of type I collagen (CTX), and procollagen type 1 N-terminal propeptide (P1NP), serum phosphate, plasma intact fibroblast growth factor 23 (FGF23), tubular maximum reabsorption rate of phosphate adjusted for glomerular filtration rate(TmP/GFR)
Efficacy Endpoints:
Skeletal, calcification, and hearing evaluations that were conducted within 2 months of enrollment can be used for Baseline if no prohibited drugs, as described in Protocol Section 9.4, were used during this period prior to enrollment and if conducted consistent with the protocol • Skeletal − Na18F-PET/CT − X-rays • Arterial and organ calcification − Na18F-PET/CT − Echocardiogram − Renal ultrasound • Ophthalmological − Angioid streaks, choroidal and subretinal neovascularization, and breaks in Bruch’s membrane as assessed by optical coherence tomography (OCT), color fundus photography, and autofluorescence photography − Best corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study letter charts − Dark Adaptation • Cardiovascular and peripheral vascular reactivity function − Echocardiogram − ECG − Ankle-brachial pressure index (ABI) − Pulse Wave Velocity (PWV) − Carotid ultrasound • Neurological function − Neurological exam • Pulmonary function − Spirometry • Performance outcomes − 2-minute walk test (2MWT), 6-minute walk test (6MWT) − Handheld dynamometry, grip strength, range of motion − Hearing tests: Physical exam and otoscopy, immittance audiometry (tympanometry), Pure Tone Audiometry (PTA), High Frequency Audiometry (HFA) • Baseline patient, clinician, and caregiver outcomes − Patient, Clinician, Caregiver Global Impression scales − Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference, Pain Intensity, Fatigue, Cognitive Function, and Physical Function - Upper Extremity − Vision Function Questionnaire − Work Productivity and Activity Impairment Questionnaire (WPAI) − Edinburgh Claudication Questionnaire (ECQ) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Safety assessments will be summarized at Baseline and at each observed time point. All assessments for Efficacy are collected at Baseline and at timepoints noted in the Schedules of Events. |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability of multiple ascending doses. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |